Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines Professional…
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive results in EGFR Exon20ins NSCLC
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive…
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat…
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…